Inventiva is a biopharmaceutical company with several drug candidates at clinical and preclinical stage.
Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 16, 2022 | Post-IPO Debt | €50M | 1 | European Investment Bank | — | Detail |
Sep 19, 2016 | Grant | €2.30M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
European Investment Bank | Yes | Post-IPO Debt |
Agence National de la Recherche | — | Grant |